TiumBio Co Ltd
321550
Company Profile
Business description
TiumBio Co Ltd is a Biopharmaceutical company. It is engaged in research and development of rare and intractable diseases. The company's products are in pipeline. It offers products such as Idiopathic pulmonary fibrosis therapies, immune chemotherapy, endometriosis therapies, hemophilia.
Contact
49, Daewangpangyo-ro 644beon-gil
Bundang-gu, 4th floor
Gyeonggi
Seongnam13493
KORT: +82 7041627320
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
51
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,477.30 | 20.70 | -0.24% |
| CAC 40 | 8,051.07 | 39.92 | -0.49% |
| DAX 40 | 22,410.27 | 15.66 | -0.07% |
| Dow JONES (US) | 43,621.16 | 159.95 | 0.37% |
| FTSE 100 | 8,668.67 | 9.69 | 0.11% |
| HKSE | 23,941.26 | 907.24 | 3.94% |
| NASDAQ | 19,026.39 | 260.54 | -1.35% |
| Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
| NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
| S&P 500 | 5,955.25 | 28.00 | -0.47% |
| S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
| SSE Composite Index | 3,380.21 | 34.17 | 1.02% |